
GILD Stock Up 3% Now, Gilead’s Remdesivir to be Available to U.S. Hospitals This Week
Following the Gilead CEO’s statement about exporting remdesivir to the U.S. hospitals, Gilead Sciences (GILD) stock is up. In the pre-market today, Gilead shares are over 3% up, trading at above $82.